anti-amyloid drugs – Page 2

By Hole Ousia July 21, 2023November 20, 2024

“The data point to beta-amyloid playing a minor aetiological role”

ABSTRACT:

By Hole Ousia July 21, 2023November 20, 2024

‘Therapy related brain damage’

By Hole Ousia July 20, 2023November 20, 2024

Estimating the true value: Aducanumab and Donanemab for Early Alzheimer Disease

By Hole Ousia July 20, 2023November 20, 2024

Anti-amyloid immunotherapies: low benefit/risk ratio

By Hole Ousia July 20, 2023November 20, 2024

Donanemab:’The results may be misleading’

By Hole Ousia July 20, 2023November 20, 2024

Donanemab: bleeding and seizures

By Hole Ousia July 20, 2023November 20, 2024

Brain volume loss due to Donanemab

By Hole Ousia July 19, 2023November 20, 2024

Donanemab [TRAILBLAZER]

On the day that this Randomised Controlled Trial was published in The Journal of the American Medical Association, 17 July 2023, headlines and news coverage TRAILBLAZED across the world [well … Continue reading Donanemab [TRAILBLAZER]